Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Donegan

Podiatrist Altoona, WI Doctor of Podiatric Medicine

NPI 1780942045 CMS profile 1341592

1200 Oakleaf Way Ste A, Altoona, WI 54720

Open in the dashboard

General payments

$3,183

17 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Donegan of Altoona, WI is reported in the CMS Open Payments database as having received $3,183 across 17 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17 1
2024 General $70 3
2022 General $22 1
2021 General $2,000 3
2020 General $870 5
2019 General $204 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Donegan
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Ryan Donegan were reported at $17. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Ryan Donegan Podiatrist median Middle half National median
2019 $204 $196 $72–$601 $163
2020 $870 $118 $38–$335 $114
2021 $2,000 $169 $57–$573 $132
2022 $22 $220 $74–$782 $149
2023 $0 $208 $71–$635 $160
2024 $70 $237 $87–$681 $164
2025 $17 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gramercy Extremity Orthopedics LLC $2,000 3 payments
  2. Paragon 28, Inc. $870 5 payments
  3. Osiris Therapeutics Inc. $188 3 payments
  4. DePuy Synthes Sales Inc. $87 4 payments
  5. Smith+Nephew, Inc. $22 1 payment
  6. Bioventus LLC $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $2,000 3 payments
  2. Travel and Lodging $836 4 payments
  3. Food and Beverage $347 10 payments
Products named General payments · program years 2019–2025
  1. GRAFIX $188 3 payments
  2. Stravix $188 3 payments
  3. GrafixPL $188 3 payments
  4. ORTHOVISC $46 2 payments
  5. MONOVISC $41 2 payments
  6. Q-FIX $22 1 payment
  7. HEALICOIL $22 1 payment
  8. MICRORAPTOR $22 1 payment
  9. Exogen $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

355

Median for Podiatry: 160

Drug cost

$21,786

Median for Podiatry: $2,368

Branded share of claims

11.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jublia Efinaconazole Brand 21 $15,881
Ketoconazole Generic 73 $1,487
Ciclopirox Generic 34 $1,424
Diclofenac Sodium Generic 26 $692
Ammonium Lactate Generic 44 $673
Clotrimazole Generic 26 $404
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 20 $375
Methylprednisolone Generic 45 $324
Gabapentin Generic 17 $287
Meloxicam Generic 27 $153

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$148,807

Of which drugs: $4

Medicare patients

337

Average age 76

Services billed

2,967

188 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 47%
Ischemic heart disease 35%
Atrial fibrillation 24%
Heart failure 23%
Chronic kidney disease 23%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 27 43 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record